Estrogens and atherosclerosis

Eur J Endocrinol. 2004 Feb;150(2):113-7. doi: 10.1530/eje.0.1500113.

Abstract

Numerous epidemiological as well as experimental studies have suggested that estradiol (E2) prevents atherosclerosis development. However two controlled prospective and randomized studies in women using hormone replacement therapy (HRT) did not confirm this beneficial effect. We then decided to use mouse models of atherosclerosis to define the possible mechanisms involved and the reasons for the discrepancy. We have shown that, although serum cholesterol decreases, this influence on lipid metabolism is negligible. Surprisingly, E2 induces an inflammatory-immune response towards a T helper cell (Th1) profile with increasing interferon-gamma production that could destabilize atheromatous plaques, and could account for the increase in the frequency of cardiovascular events in women undergoing HRT. At the level of the endothelium, E2 induces an increase in nitric oxide (NO) biodisponibility, but this phenomenon does not concern the development of fatty streaks. Nevertheless, the atheroprotective effect is apparently mediated at the level of the endothelium by a mechanism that has still to be characterized in molecular terms. These new acquisitions constitute a basis for new pharmacological developments allowing the prevention of deleterious effects and preserving the beneficial ones.

Publication types

  • Review

MeSH terms

  • Animals
  • Arteriosclerosis / immunology
  • Arteriosclerosis / physiopathology*
  • Disease Models, Animal
  • Endothelium, Vascular / physiopathology*
  • Estradiol / metabolism*
  • Female
  • Humans
  • Inflammation / physiopathology
  • Mice
  • Mice, Knockout
  • Th1 Cells / physiology

Substances

  • Estradiol